Specifically addressing cell surface molecules on cancer cells facilitates targeted cancer therapies that offer the potential to selectively destroy malignant cells, while sparing healthy tissue. Thus, undesired side-effects in tumor patients are highly reduced. Peptide-binding receptors are frequently overexpressed on cancer cells and therefore promising targets for selective tumor therapy. In this review, peptide-binding receptors for anti-cancer drug delivery are summarized with a focus on peptide ligands as delivery agents. In the first part, some of the most studied peptide-binding receptors are presented, and the ghrelin receptor and the Y1 receptor are introduced as more recent targets for cancer therapy. Furthermore, nonpeptidic small molecules for receptor targeting on cancer cells are outlined. In the second part, peptide conjugates for the delivery of therapeutic cargos in cancer therapy are described. The essential properties of receptor-targeting peptides are specified, and recent developments in the fields of classical peptide-drug conjugates with toxic agents, radiolabeled peptides for radionuclide therapy, and boronated peptides for boron neutron capture therapy are presented.

Cancer became recently the leading cause of death in industrialized countries. Even though standard treatments achieve significant effects in growth inhibition and tumor elimination, they cause severe side effects as most of the applied drugs exhibit only minor selectivity for the malignant tissue. Hence, specific addressing of tumor cells without affecting healthy tissue is currently a major desire in cancer therapy. Cell surface receptors, which bind peptides are frequently overexpressed on cancer cells and can therefore be considered as promising targets for selective tumor therapy. In this review, the benefits of peptides as tumor homing agents are presented and an overview of the most commonly addressed peptide receptors is given. A special focus was set on the bombesin receptor family and the neuropeptide Y receptor family. In the second part, the specific requirements of peptide-drug conjugates (PDC) and intelligent linker structures as an essential component of PDC are outlined. Furthermore, different drug cargos are presented including classical and recent toxic agents as well as radionuclides for diagnostic and therapeutic approaches. In the last part, boron neutron capture therapy as advanced targeted cancer therapy is introduced and past and recent developments are reviewed.

In the post-genomic era, recognition of the importance of sugars is increasing in biological research. For the precise analysis of their functions, homogeneous materials are required. Chemical synthesis is a powerful tool for preparation of homogeneous oligosaccharides and glycoconjugates. Glycosidases are potent catalysts for this purpose because they realize high stereo- and regio- selectivities under conditions benign to biomolecules without repetitive protection/deprotection procedures. A glycosynthase is an aritificial enzyme which is derived from a glycosidase and is devised for glycosylation reaction. To suppress the mechanistically inherent oligomerization side reaction of this class of biocatalysts, a glycosidase with plastic substrate recognition was engineered to afford the first α-mannosynthase. This novel biocatalyst showed low occurrence of oligomerized products as designed and was applied to prepare a wide range of oligosaccharides. Glycosidases are also valuable tools for glycan engineering of glycoconjugates, which is a pivotal issue in the development of pharmaceutical agents, including immunoglobulin G (IgG)-based drugs. EndoS, an endo-β-N-acetylglucosaminidase from Streptococcus pyogenes, natively cleaves N-glycans on IgG specifically. When the latent glycosylation activity of this enzyme was applied, the N-glycan remodelling of full-length IgG was successfully achieved for the first time and a highly pure glycoform was obtained using the chemically synthesized oxazoline tetrasaccharide as glycosyl donor. This biocatalytic reaction allows development of a novel type of antibody-drug conjugates (ADCs) in which drug molecules are linked to N-glycans site-specifically. For this purpose, glycans with bioorthogonal reaction handles were synthesized and conjugated to IgG. A model reaction using a dye compound as reaction partner worked successfully and the synthetic method for this newly designed ADC was validated. Glycan trimming of glycoproteins expressed from Pichia pastoris was performed using exoglycosidases to derive homogeneous glycoform. Jack Bean α-mannosidase (JBM) trimmed native N-glycans down to the core trisaccharide structure but some of the glycoforms were discovered to be resistant to the JBM activity. Enzymatic analyses using exoglycosidases suggested that the JBM-resistant factor was likely to be β-mannoside. In summary, this work advanced application of modified glycosidases for preparation of oligosaccharides and also demonstrated biocatalytic utility of glycosidases to produce biologically relevant glycoconjugates with homogeneous glycoforms.

<p>LC-MS of protein drugs requires new ideas in bonded phase design rather than adapting bonded phases from the realm of small-molecule drugs. The polymer-shell bonded phase is designed to interact with larger molecules and to shield proteins from the silica substrate. The particles consist of a core of solid silica and a shell of dense polymer brush. The polymer layer is thick enough to protect the protein from interactions with silanols to reduce peak tailing. The polymer contains multiple functional groups that introduce more selectivity. This design gives unprecedented LC resolution and MS sensitivity. Our group has developed polymer shell bonded phases for hydrophobic interaction chromatography (HIC-MS) of antibody-drug conjugates (ADCs), hydrophilic interaction liquid chromatography (HILIC-MS) of glycoproteins, and reversed-phase liquid chromatography (RPLC-MS) of monoclonal antibodies. Since HIC is not in-line compatible with MS due to the high salt levels, it is laborious to identify the constituents of HIC peaks. An MS-compatible alternative to HIC is reported here: native reversed phase liquid chromatography (nRPLC). This employs a mobile phase 50 mM ammonium acetate for high sensitivity in MS, and elution with a gradient of water/isopropanol. The nRPLC-MS data show that all ADC species, ranging from drug-to-antibody ratios of 1 to 8, remained intact and native on the column. As we adapt this concept to intact proteins, we find that lysozyme and α-chymotrypsinogen A are both eluted in their native conformations. We also use the polymer-shell concept to resolve IgG1 free thiol variants by RPLC-MS with 0.5% formic acid. Since there are always other variants besides the intended ones, the need for high MS sensitivity is desired to distinguish subtle mass change between disulfide bond and free thiols. Overall, MS sensitivity increases 10X relative while all of the thiol variants are well resolved by the polymethylmethacrylate bonded phase.</p>

In this thesis will be described research towards the development of bioorthogonal bond-cleavage reactions, and their applications in targeted drug delivery (Figure 1). The first project relates to the development of a palladium mediated bond-cleavage or "decaging" reaction which can cause a propargyl carbamate to decompose and release an amine. This was further developed by the incorporation of a protein modification handle which allowed an amine-bearing drug to be covalently ligated to a protein by a palladium-cleavable linker. This chemistry was demonstrated by the conjugation of the anticancer drug doxorubicin to a tumour targeted anti-HER2 nanobody. The drug could then be delivered to cancer cells upon addition of a palladium complex. The second project relates to the development of a platinum mediated bond-cleavage reaction. This was developed with the aim of using platinum-containing anticancer drugs - such as cisplatin - as a catalyst to cause drug release reactions in tumours. In this reaction an alkyne-containing amide can decompose to release an amine upon addition of platinum complexes, and was applied to the release of prodrugs of the cytotoxins monomethylauristatin E and 5-fluorouracil in cancer cells. A cisplatin-cleavable antibody-drug conjugate was designed and synthesised, and progress towards its biological evaluation will be discussed.

No description available.

In dieser Arbeit wurden ungesättigte Vinyl- und Ethynylphosphonothiolate hergestellt und als Linker für Cystein-selektive Proteinmodifikationen verwendet. Zunächst wurde, ausgehend von ungesättigten Phosphoniten und elektrophilen Disulfiden als Startmaterialien, eine Syntheseroute zur Herstellung von ungesättigten Phosphonothiolaten entwickelt. Die hohe Chemoselektivität dieser Reaktion ermöglichte die Einführung von Vinylphosphonothiolaten auf ungeschützten Modellpeptiden und dem Protein Ubiquitin. Es konnte gezeigt werden, dass ungesättigte Phosphonothiolate unter neutralen bis leicht basischen Bedingungen selektiv mit Thiolen reagieren und sich daher als Linker für Cystein-selektive Proteinmodifikationen eignen. Die Vielseitigkeit der hier entwickelten Biokonjugationsmethode wurde in drei Anwendungen demonstriert. Ausgehend von dem Vinylphoshonothiolat-modifizierten Ubiquitin konnten homogene Ubiquitin-Protein-Konjugate erzeugt werden; zum einen ein nicht hydrolysierbares Diubiquitin-Konjugat und zum anderen ein Ubiquitin-α–Synuclein-Konjugat. Des Weiteren wurden ungesättigte Phosphonothiolate als Linker in Antikörper-Wirkstoff-Konjugaten getestet. Hier zeigte sich, dass insbesondere Vinylphosphonothiolat-Linker Potential zur Herstellung von stabilen Antikörper-Konjugaten aufweisen. Schließlich wurden Vinylphosphonothiolate als Linker verwendet, um sowohl Chaperon-bindende Antikörper als auch Deubiquitinasen (DUBs) mit photoreaktiven Crosslinkern auszustatten um damit dynamische Protein-Interaktionen zu untersuchen. Insgesamt ermöglicht das hier entwickelte Verfahren die chemoselektive Umwandlung von elektrophilen Disulfiden in elektrophile Vinyl- und Ethynylphosphonothiolate, wodurch Reaktivität für eine Thioladdition induziert wird. Dadurch können zwei komplexe, thiolhaltige Moleküle selektiv konjugiert werden, was insbesondere für die Herstellung von homogen modifizierten Peptid- und Proteinkonjugaten von Bedeutung ist. / In this work, unsaturated vinyl- and ethynylphosphonothiolates were synthesised and used as linkers for cysteine-selective protein modifications. First, a synthetic route for the generation of unsaturated phosphonothiolates was developed, using unsaturated phosphonites and electrophilic disulfides as starting materials. The high chemoselectivity of this reaction enabled the introduction of vinylphosphonothiolates on unprotected model peptides and the protein ubiquitin. It could then be shown that unsaturated phosphonothiolates react selectively with thiols under neutral to slightly basic conditions and are therefore suitable as linkers for cysteine-selective protein modifications. The versatility of the herein developed bioconjugation method was demonstrated in three applications. First, starting from the vinylphosphonothiolate-modified ubiquitin, homogeneous ubiquitin-protein conjugates could be generated, in particular a non-hydrolyzable diubiquitin conjugate and a ubiquitin-α-synuclein conjugate. Second, the suitability of unsaturated phosphonothiolates as linkers for the generation of stable antibody-drug conjugates was tested. Vinylphosphonothiolate linkers thereby showed potential to produce stable antibody conjugates. Finally, vinylphosphonothiolates were used as linkers to conjugate both chaperone-binding antibodies and deubiquitinases (DUBs) to photo-reactive crosslinkers in order to investigate dynamic protein interactions. Overall, the herein developed methodology enables the chemoselective conversion of electrophilic disulfides into electrophilic vinyl- and ethynylphosphonothiolates, which in turn react selectively with thiols. As a result, two complex, thiol-containing molecules can be selectively conjugated, which is particularly important for the production of homogeneously modified peptide and protein conjugates.